BeiGene Says BRUKINSA Data At American Society Of Clinical Oncology (ASCO) Annual Meeting In Chicago Underscore Differentiated Clinical Profile For Treatment Of CLL And SLL
Portfolio Pulse from Benzinga Newsdesk
BeiGene presented data at the ASCO Annual Meeting highlighting the efficacy and safety of BRUKINSA for treating CLL and SLL. The data showed improved progression-free survival (PFS) and response rates, along with low usage of antihypertensive medicines compared to other BTK inhibitors.
May 24, 2024 | 10:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BeiGene's presentation at ASCO highlighted BRUKINSA's superior clinical profile for treating CLL and SLL, showing improved PFS and response rates, which could positively impact the stock price.
The positive clinical data presented at a major oncology conference like ASCO is likely to boost investor confidence in BeiGene's BRUKINSA, potentially leading to a short-term increase in BGNE's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100